Overview

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Treatments:
Lenalidomide